Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin G Hale

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
EMBO Reports|August 16, 2021
BRD9 is a druggable component of interferon-stimulated gene expression and antiviral activityJacob Börold, Davide Eletto, Idoia Busnadiego, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 4, 2021
Influenza A viruses balance ER stress with host protein synthesis shutoffBeryl Mazel-Sanchez, Justyna Iwaszkiewicz, Joao P P Bonifacio, et al.
Nature Cell Biology|March 14, 2026
An SP110-SP100 axis is a critical regulator of promyelocytic leukaemia body dynamics and mitotic fidelityEric J Aird, Julius Rabl, Tabea Knuesel, et al.
The Journal of Experimental Medicine|April 21, 2021
IFITM3 incorporation sensitizes influenza A virus to antibody-mediated neutralizationCaroline Lanz, Michael Schotsaert, Carsten Magnus, et al.
Journal of Virology|March 9, 2012
Influenza virus sequence feature variant type analysis: evidence of a role for NS1 in influenza virus host range restrictionJyothi M Noronha, Mengya Liu, R Burke Squires, et al.
Plos Pathogens|June 17, 2021
Manipulation of the unfolded protein response: A pharmacological strategy against coronavirus infectionLiliana Echavarría-Consuegra, Georgia M Cook, Idoia Busnadiego, et al.
Nature Nanotechnology|June 4, 2021
An antiviral trap made of protein nanofibrils and iron oxyhydroxide nanoparticlesArchana Palika, Antonius Armanious, Akram Rahimi, et al.
The Journal of Experimental Medicine|March 20, 2025
Type I interferon autoantibody footprints reveal neutralizing mechanisms and allow inhibitory decoy designKevin Groen, Roger Kuratli, Jannik Enkelmann, et al.
Open Forum Infectious Diseases|January 5, 2024
Absence of Type I Interferon Autoantibodies or Significant Interferon Signature Alterations in Adults With Post-COVID-19 SyndromeMartin Achleitner, Nina K Mair, Juliane Dänhardt, et al.
The Journal of Experimental Medicine|July 17, 2024
Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodiesSonja Fernbach, Nina K Mair, Irene A Abela, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
EMBO Reports|August 16, 2021
BRD9 is a druggable component of interferon-stimulated gene expression and antiviral activityJacob Börold, Davide Eletto, Idoia Busnadiego, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 4, 2021
Influenza A viruses balance ER stress with host protein synthesis shutoffBeryl Mazel-Sanchez, Justyna Iwaszkiewicz, Joao P P Bonifacio, et al.
Nature Cell Biology|March 14, 2026
An SP110-SP100 axis is a critical regulator of promyelocytic leukaemia body dynamics and mitotic fidelityEric J Aird, Julius Rabl, Tabea Knuesel, et al.
The Journal of Experimental Medicine|April 21, 2021
IFITM3 incorporation sensitizes influenza A virus to antibody-mediated neutralizationCaroline Lanz, Michael Schotsaert, Carsten Magnus, et al.
Journal of Virology|March 9, 2012
Influenza virus sequence feature variant type analysis: evidence of a role for NS1 in influenza virus host range restrictionJyothi M Noronha, Mengya Liu, R Burke Squires, et al.
Plos Pathogens|June 17, 2021
Manipulation of the unfolded protein response: A pharmacological strategy against coronavirus infectionLiliana Echavarría-Consuegra, Georgia M Cook, Idoia Busnadiego, et al.
Nature Nanotechnology|June 4, 2021
An antiviral trap made of protein nanofibrils and iron oxyhydroxide nanoparticlesArchana Palika, Antonius Armanious, Akram Rahimi, et al.
The Journal of Experimental Medicine|March 20, 2025
Type I interferon autoantibody footprints reveal neutralizing mechanisms and allow inhibitory decoy designKevin Groen, Roger Kuratli, Jannik Enkelmann, et al.
Open Forum Infectious Diseases|January 5, 2024
Absence of Type I Interferon Autoantibodies or Significant Interferon Signature Alterations in Adults With Post-COVID-19 SyndromeMartin Achleitner, Nina K Mair, Juliane Dänhardt, et al.
The Journal of Experimental Medicine|July 17, 2024
Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodiesSonja Fernbach, Nina K Mair, Irene A Abela, et al.
Pageof 7